Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00262990




Registration number
NCT00262990
Ethics application status
Date submitted
6/12/2005
Date registered
7/12/2005
Date last updated
17/12/2020

Titles & IDs
Public title
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Scientific title
A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer
Secondary ID [1] 0 0
CEPO906A2303
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ovarian Cancer 0 0
Fallopian Tube Cancer 0 0
Peritoneal Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)
Cancer 0 0 0 0
Stomach

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Patupilone -

Active comparator: doxorubicin -

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer
Timepoint [1] 0 0
every 8 weeks
Secondary outcome [1] 0 0
To determine the duration of overall response in patients with complete response (CR) or partial response (PR) or stable disease (SD)
Timepoint [1] 0 0
End of study
Secondary outcome [2] 0 0
To determine the progression-free survival (PFS) of patients treated with patupilone
Timepoint [2] 0 0
end of study
Secondary outcome [3] 0 0
To determine the time to disease progression (TTP) of patients treated with patupilone
Timepoint [3] 0 0
end of study
Secondary outcome [4] 0 0
To determine overall best tumor response (CR, PR, SD, PD and Unknown)
Timepoint [4] 0 0
end of study
Secondary outcome [5] 0 0
To investigate the safety and tolerability of patupilone
Timepoint [5] 0 0
end of study
Secondary outcome [6] 0 0
To evaluate the pharmacokinetics (PK) of patupilone from all patients
Timepoint [6] 0 0
end of study
Secondary outcome [7] 0 0
To explore relationships between Cmin (pre-dose patupilone blood concentration) and efficacy/adverse events
Timepoint [7] 0 0
end of study

Eligibility
Key inclusion criteria
* 18 years of age or older
* Confirmed diagnosis of ovarian, fallopian or peritoneal cancer
* No more than three chemotherapy regimens
* Most recent regimen must have been platinum based
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Have an unresolved bowel obstruction
* Have had previous chemotherapy within 3 weeks
* Recovering from any surgery for any cause

Other protocol-defined inclusion/exclusion criteria will apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
829
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Novartis Investigative Site - Adelaide
Recruitment hospital [2] 0 0
Novartis Investigative Site - Herston
Recruitment hospital [3] 0 0
Novartis Investigative Site - Nedlands, WA
Recruitment hospital [4] 0 0
Novartis Investigative Site - South Brisbane
Recruitment hospital [5] 0 0
Novartis Investigative Site - St. Leonards
Recruitment hospital [6] 0 0
Novartis Investigative Site - Wodonga
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Herston
Recruitment postcode(s) [3] 0 0
- Nedlands, WA
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment postcode(s) [5] 0 0
- St. Leonards
Recruitment postcode(s) [6] 0 0
- Wodonga
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alaska
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Delaware
Country [8] 0 0
United States of America
State/province [8] 0 0
District of Columbia
Country [9] 0 0
United States of America
State/province [9] 0 0
Florida
Country [10] 0 0
United States of America
State/province [10] 0 0
Georgia
Country [11] 0 0
United States of America
State/province [11] 0 0
Hawaii
Country [12] 0 0
United States of America
State/province [12] 0 0
Illinois
Country [13] 0 0
United States of America
State/province [13] 0 0
Indiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Kentucky
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Minnesota
Country [19] 0 0
United States of America
State/province [19] 0 0
Mississippi
Country [20] 0 0
United States of America
State/province [20] 0 0
Missouri
Country [21] 0 0
United States of America
State/province [21] 0 0
Nebraska
Country [22] 0 0
United States of America
State/province [22] 0 0
Nevada
Country [23] 0 0
United States of America
State/province [23] 0 0
New Hampshire
Country [24] 0 0
United States of America
State/province [24] 0 0
New Jersey
Country [25] 0 0
United States of America
State/province [25] 0 0
New York
Country [26] 0 0
United States of America
State/province [26] 0 0
North Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oklahoma
Country [29] 0 0
United States of America
State/province [29] 0 0
Oregon
Country [30] 0 0
United States of America
State/province [30] 0 0
Pennsylvania
Country [31] 0 0
United States of America
State/province [31] 0 0
South Carolina
Country [32] 0 0
United States of America
State/province [32] 0 0
Tennessee
Country [33] 0 0
United States of America
State/province [33] 0 0
Texas
Country [34] 0 0
United States of America
State/province [34] 0 0
Utah
Country [35] 0 0
United States of America
State/province [35] 0 0
Vermont
Country [36] 0 0
United States of America
State/province [36] 0 0
Virginia
Country [37] 0 0
United States of America
State/province [37] 0 0
Washington
Country [38] 0 0
United States of America
State/province [38] 0 0
Wisconsin
Country [39] 0 0
Canada
State/province [39] 0 0
British Columbia
Country [40] 0 0
Canada
State/province [40] 0 0
Calgary
Country [41] 0 0
Canada
State/province [41] 0 0
Montreal
Country [42] 0 0
Canada
State/province [42] 0 0
North York
Country [43] 0 0
Canada
State/province [43] 0 0
Quebec
Country [44] 0 0
Canada
State/province [44] 0 0
Sherbrooke
Country [45] 0 0
Canada
State/province [45] 0 0
Toronto
Country [46] 0 0
Denmark
State/province [46] 0 0
Odense
Country [47] 0 0
Denmark
State/province [47] 0 0
Vejle
Country [48] 0 0
Finland
State/province [48] 0 0
Helsinki
Country [49] 0 0
Finland
State/province [49] 0 0
Kuopio
Country [50] 0 0
Finland
State/province [50] 0 0
Tampere
Country [51] 0 0
France
State/province [51] 0 0
Amboise
Country [52] 0 0
France
State/province [52] 0 0
Bordeaux
Country [53] 0 0
France
State/province [53] 0 0
Caen Cedex
Country [54] 0 0
France
State/province [54] 0 0
Herblain Cedec
Country [55] 0 0
France
State/province [55] 0 0
Villejuif Cedex
Country [56] 0 0
Greece
State/province [56] 0 0
Athens
Country [57] 0 0
Italy
State/province [57] 0 0
Bologna
Country [58] 0 0
Italy
State/province [58] 0 0
Milano
Country [59] 0 0
Italy
State/province [59] 0 0
Modena
Country [60] 0 0
Italy
State/province [60] 0 0
Monza
Country [61] 0 0
Italy
State/province [61] 0 0
Padova
Country [62] 0 0
Italy
State/province [62] 0 0
Roma
Country [63] 0 0
Italy
State/province [63] 0 0
Torino
Country [64] 0 0
Poland
State/province [64] 0 0
Krakow
Country [65] 0 0
South Africa
State/province [65] 0 0
Cape Town
Country [66] 0 0
South Africa
State/province [66] 0 0
Johannesburg, Gauteng
Country [67] 0 0
South Africa
State/province [67] 0 0
Klerksdorp
Country [68] 0 0
South Africa
State/province [68] 0 0
Port Elizabeth
Country [69] 0 0
South Africa
State/province [69] 0 0
Pretoria, Gauteng
Country [70] 0 0
South Africa
State/province [70] 0 0
Pretoria, Guateng
Country [71] 0 0
South Africa
State/province [71] 0 0
Sandton, Gauteng
Country [72] 0 0
Spain
State/province [72] 0 0
Barcelona
Country [73] 0 0
Spain
State/province [73] 0 0
Madrid
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Glasgow
Country [75] 0 0
United Kingdom
State/province [75] 0 0
London
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Wirral
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00262990